IL96893A - Vaccines against cancer and infectious diseases - Google Patents

Vaccines against cancer and infectious diseases

Info

Publication number: IL96893A
Authority: IL; Israel
Prior art keywords: antibody; antigen; antibodies; vaccine; idiotype
Prior art date: 1990-01-26

Application number

IL9689391A

Other languages

English (en)

Other versions

IL96893A0 (en

Original Assignee

Immunomedics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-01-26

Filing date

1991-01-07

Publication date

1994-06-24

1991-01-07 Application filed by Immunomedics Inc filed Critical Immunomedics Inc

1992-03-29 Publication of IL96893A0 publication Critical patent/IL96893A0/xx

1994-06-24 Publication of IL96893A publication Critical patent/IL96893A/en

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 29
201000011510 cancer Diseases 0.000 title claims description 16
206010028980 Neoplasm Diseases 0.000 title abstract description 47
208000035473 Communicable disease Diseases 0.000 title description 4
239000000427 antigen Substances 0.000 claims abstract description 83
102000036639 antigens Human genes 0.000 claims abstract description 82
108091007433 antigens Proteins 0.000 claims abstract description 82
230000003302 anti-idiotype Effects 0.000 claims abstract description 48
241000282414 Homo sapiens Species 0.000 claims abstract description 24
108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 23
102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 23
230000002163 immunogen Effects 0.000 claims abstract description 21
238000000034 method Methods 0.000 claims abstract description 21
239000012678 infectious agent Substances 0.000 claims abstract description 20
244000045947 parasite Species 0.000 claims abstract description 20
230000003278 mimic effect Effects 0.000 claims abstract description 18
241000288906 Primates Species 0.000 claims abstract description 17
230000028993 immune response Effects 0.000 claims abstract description 16
241000700605 Viruses Species 0.000 claims abstract description 11
230000003211 malignant effect Effects 0.000 claims abstract description 11
230000004936 stimulating effect Effects 0.000 claims abstract description 5
241000894006 Bacteria Species 0.000 claims abstract description 4
241000233866 Fungi Species 0.000 claims abstract description 3
241000204031 Mycoplasma Species 0.000 claims abstract description 3
241000606701 Rickettsia Species 0.000 claims abstract description 3
241001504519 Papio ursinus Species 0.000 claims description 46
108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 25
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 25
238000002360 preparation method Methods 0.000 claims description 13
208000015181 infectious disease Diseases 0.000 claims description 10
239000002671 adjuvant Substances 0.000 claims description 9
244000005700 microbiome Species 0.000 claims description 6
241001467552 Mycobacterium bovis BCG Species 0.000 claims description 5
230000000259 anti-tumor effect Effects 0.000 claims description 5
229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims description 5
230000002458 infectious effect Effects 0.000 claims description 5
210000001006 meconium Anatomy 0.000 claims description 4
102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims description 3
101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims description 3
230000002223 anti-pathogen Effects 0.000 claims description 3
230000003902 lesion Effects 0.000 claims description 3
210000004072 lung Anatomy 0.000 claims description 3
206010039491 Sarcoma Diseases 0.000 claims description 2
229940037003 alum Drugs 0.000 claims description 2
210000004556 brain Anatomy 0.000 claims description 2
210000000481 breast Anatomy 0.000 claims description 2
230000002496 gastric effect Effects 0.000 claims description 2
201000005787 hematologic cancer Diseases 0.000 claims description 2
230000001926 lymphatic effect Effects 0.000 claims description 2
201000001441 melanoma Diseases 0.000 claims description 2
230000002611 ovarian Effects 0.000 claims description 2
210000002307 prostate Anatomy 0.000 claims description 2
230000002381 testicular Effects 0.000 claims description 2
229960000814 tetanus toxoid Drugs 0.000 claims description 2
208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
229960001438 immunostimulant agent Drugs 0.000 claims 1
239000003022 immunostimulating agent Substances 0.000 claims 1
230000003308 immunostimulating effect Effects 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 abstract description 12
230000036039 immunity Effects 0.000 abstract description 6
230000003449 preventive effect Effects 0.000 abstract description 4
241000282520 Papio Species 0.000 abstract description 2
230000001939 inductive effect Effects 0.000 abstract description 2
108060003951 Immunoglobulin Proteins 0.000 description 27
102000018358 immunoglobulin Human genes 0.000 description 27
239000012634 fragment Substances 0.000 description 20
230000003053 immunization Effects 0.000 description 19
238000002649 immunization Methods 0.000 description 19
244000052769 pathogen Species 0.000 description 15
241001529936 Murinae Species 0.000 description 14
229940072221 immunoglobulins Drugs 0.000 description 14
238000004519 manufacturing process Methods 0.000 description 13
230000001717 pathogenic effect Effects 0.000 description 13
241001465754 Metazoa Species 0.000 description 12
238000002347 injection Methods 0.000 description 12
239000007924 injection Substances 0.000 description 12
210000004027 cell Anatomy 0.000 description 10
241000282412 Homo Species 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
230000002494 anti-cea effect Effects 0.000 description 8
241000713772 Human immunodeficiency virus 1 Species 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 7
244000000010 microbial pathogen Species 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
208000030507 AIDS Diseases 0.000 description 5
230000008901 benefit Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
210000004408 hybridoma Anatomy 0.000 description 5
230000005847 immunogenicity Effects 0.000 description 5
210000003936 merozoite Anatomy 0.000 description 5
230000000813 microbial effect Effects 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
238000002965 ELISA Methods 0.000 description 4
206010035226 Plasma cell myeloma Diseases 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
201000000050 myeloid neoplasm Diseases 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
230000007017 scission Effects 0.000 description 4
210000003046 sporozoite Anatomy 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000011282 treatment Methods 0.000 description 4
241000283707 Capra Species 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
241000223960 Plasmodium falciparum Species 0.000 description 3
241000700159 Rattus Species 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000005875 antibody response Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000002860 competitive effect Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
230000004927 fusion Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000016784 immunoglobulin production Effects 0.000 description 3
239000000203 mixture Substances 0.000 description 3
229920000136 polysorbate Polymers 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
238000002255 vaccination Methods 0.000 description 3
238000005406 washing Methods 0.000 description 3
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
108090000565 Capsid Proteins Proteins 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
101100174574 Mus musculus Pikfyve gene Proteins 0.000 description 2
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
108090000526 Papain Proteins 0.000 description 2
102000057297 Pepsin A Human genes 0.000 description 2
108090000284 Pepsin A Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
241000223997 Toxoplasma gondii Species 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
230000036436 anti-hiv Effects 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
230000006472 autoimmune response Effects 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
230000003196 chaotropic effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
238000005497 microtitration Methods 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
229940055729 papain Drugs 0.000 description 2
235000019834 papain Nutrition 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
229940111202 pepsin Drugs 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
-1 portions thereof Substances 0.000 description 2
238000011533 pre-incubation Methods 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
241000894007 species Species 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000004797 therapeutic response Effects 0.000 description 2
125000003396 thiol group Chemical class [H]S* 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
241000203022 Acholeplasma laidlawii Species 0.000 description 1
241000223838 Babesia bovis Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000589969 Borreliella burgdorferi Species 0.000 description 1
241000589567 Brucella abortus Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
241000700198 Cavia Species 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
201000003808 Cystic echinococcosis Diseases 0.000 description 1
206010011831 Cytomegalovirus infection Diseases 0.000 description 1
241000725619 Dengue virus Species 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241000244170 Echinococcus granulosus Species 0.000 description 1
102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
208000002476 Falciparum Malaria Diseases 0.000 description 1
241000714165 Feline leukemia virus Species 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
206010061187 Haematopoietic neoplasm Diseases 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
241000588747 Klebsiella pneumoniae Species 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
241000589248 Legionella Species 0.000 description 1
208000007764 Legionnaires' Disease Diseases 0.000 description 1
241000222736 Leishmania tropica Species 0.000 description 1
241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
241000520674 Mesocestoides corti Species 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
241000186362 Mycobacterium leprae Species 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
241000204028 Mycoplasma arginini Species 0.000 description 1
241000202956 Mycoplasma arthritidis Species 0.000 description 1
241000202938 Mycoplasma hyorhinis Species 0.000 description 1
241000202894 Mycoplasma orale Species 0.000 description 1
241000202889 Mycoplasma salivarium Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
241000588650 Neisseria meningitidis Species 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000243985 Onchocerca volvulus Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
241000223810 Plasmodium vivax Species 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
241000711798 Rabies lyssavirus Species 0.000 description 1
241000702263 Reovirus sp. Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000710799 Rubella virus Species 0.000 description 1
241000242680 Schistosoma mansoni Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
241000710960 Sindbis virus Species 0.000 description 1
241000589970 Spirochaetales Species 0.000 description 1
241000193985 Streptococcus agalactiae Species 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
241001672171 Taenia hydatigena Species 0.000 description 1
241000244154 Taenia ovis Species 0.000 description 1
241000244159 Taenia saginata Species 0.000 description 1
108010055044 Tetanus Toxin Proteins 0.000 description 1
241000223779 Theileria parva Species 0.000 description 1
201000005485 Toxoplasmosis Diseases 0.000 description 1
241000589884 Treponema pallidum Species 0.000 description 1
241000243777 Trichinella spiralis Species 0.000 description 1
241000223105 Trypanosoma brucei Species 0.000 description 1
241000223109 Trypanosoma cruzi Species 0.000 description 1
241000223097 Trypanosoma rangeli Species 0.000 description 1
241000711975 Vesicular stomatitis virus Species 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000000078 anti-malarial effect Effects 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
210000001815 ascending colon Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
229940056450 brucella abortus Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
210000001217 buttock Anatomy 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
210000000973 gametocyte Anatomy 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000002480 immunoprotective effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940043515 other immunoglobulins in atc Drugs 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
235000020004 porter Nutrition 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
244000000040 protozoan parasite Species 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
108700024015 reovirus sigma 1 Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
210000001563 schizont Anatomy 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000003375 selectivity assay Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
229940118376 tetanus toxin Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940096911 trichinella spiralis Drugs 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
239000000439 tumor marker Substances 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
235000002374 tyrosine Nutrition 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Virology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

IL9689391A 1990-01-26 1991-01-07 Vaccines against cancer and infectious diseases IL96893A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US47063790A	1990-01-26	1990-01-26

Publications (2)

Publication Number	Publication Date
IL96893A0 IL96893A0 (en)	1992-03-29
IL96893A true IL96893A (en)	1994-06-24

Family

ID=23868391

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9689391A IL96893A (en)	1990-01-26	1991-01-07	Vaccines against cancer and infectious diseases

Country Status (12)

Country	Link
US (2)	US6440416B1 (de)
EP (1)	EP0438803B1 (de)
JP (1)	JP2919071B2 (de)
AT (1)	ATE149841T1 (de)
AU (1)	AU641470B2 (de)
CA (1)	CA2033640C (de)
DE (1)	DE69030172T2 (de)
IE (1)	IE910265A1 (de)
IL (1)	IL96893A (de)
SG (1)	SG46445A1 (de)
WO (1)	WO1991011465A1 (de)
ZA (1)	ZA91559B (de)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7393682B1 (en)	1993-03-19	2008-07-01	The Johns Hopkins University School Of Medicine	Polynucleotides encoding promyostatin polypeptides
ATE303160T1 (de) *	1993-08-11	2005-09-15	Jenner Technologies	Impfstoff gegen prostatakrebs
US5798100A (en) *	1994-07-06	1998-08-25	Immunomedics, Inc.	Multi-stage cascade boosting vaccine
US7354587B1 (en)	1994-07-06	2008-04-08	Immunomedics, Inc.	Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
ES2197217T3 (es) *	1994-12-28	2004-01-01	University Of Kentucky Research Foundation	Anticuerpo 3h1 monoclonal anti-id-murino.
US6949244B1 (en)	1995-12-20	2005-09-27	The Board Of Trustees Of The University Of Kentucky	Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US5763216A (en) *	1995-06-07	1998-06-09	The United States Of America As Represented By The Department Of Health & Human Services	Gene encoding a human reduced folate carrier (RFC)
US5716788A (en) *	1995-06-07	1998-02-10	The United States Of America As Represented By The Department Of Health And Human Services	Antibodies to human reduced folate carrier protein
JP2000503003A (ja)	1995-12-22	2000-03-14	イムノメディクス，インコーポレイテッド	多段階カスケード増強ワクチンの効果を高めるための免疫接合体の使用
US6730300B2 (en)	1996-03-20	2004-05-04	Immunomedics, Inc.	Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
US20020041872A1 (en)	1996-04-12	2002-04-11	Malaya Chatterjee	Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6235280B1 (en)	1996-04-12	2001-05-22	Malaya Chatterjee	Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6090381A (en)	1997-02-11	2000-07-18	Immunomedics, Inc.	Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope
US6306393B1 (en)	1997-03-24	2001-10-23	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en)	1997-03-24	2001-02-06	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6274143B1 (en)	1997-06-13	2001-08-14	Malaya Chatterjee	Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6891082B2 (en)	1997-08-01	2005-05-10	The Johns Hopkins University School Of Medicine	Transgenic non-human animals expressing a truncated activintype II receptor
AU737717B2 (en) *	1997-08-13	2001-08-30	Uab Research Foundation, The	Vaccination by topical application of genetic vectors
WO1999045018A1 (en) *	1998-03-06	1999-09-10	Imclone Systems Incorporated	Active immunization against angiogenesis-associated antigens
US7157418B1 (en)	1998-07-22	2007-01-02	Osprey Pharmaceuticals, Ltd.	Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6652836B2 (en)	1998-10-15	2003-11-25	Fluoroprobe, Inc.	Method for viewing tumor tissue located within a body cavity
DE69942782D1 (de)	1998-11-27	2010-10-28	Ucb Sa	Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung
US20040009535A1 (en)	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
SK288176B6 (sk)	1999-01-07	2014-04-02	Zymogenetics, Inc.	Farmaceutický prostriedok obsahujúci fúzny proteín, izolovaná molekula polynukleotidu, expresný vektor, kultivovaná bunka, spôsob prípravy polypeptidu a izolovaný polypeptid
US7833529B1 (en)	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
EP1194167B1 (de)	1999-06-09	2009-08-19	Immunomedics, Inc.	Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
ES2286029T3 (es)	1999-07-07	2007-12-01	Zymogenetics Inc	Receptor de citocina humano.
EP3225632B1 (de)	1999-11-30	2020-05-06	Mayo Foundation for Medical Education and Research	An b7-h1, ein neuartiges immunregulierendes molekül bindende antikörper
RU2172182C1 (ru) *	2000-07-27	2001-08-20	Бритов Василий Александрович	Способ профилактики и лечения заболеваний иммунной системы и средство для его осуществления
AU2002216650A1 (en)	2000-10-31	2002-05-15	Lynn Bonham	Triazine derivatives as lpaat-b inhibitors and uses thereof
US6890734B2 (en)	2000-11-10	2005-05-10	Schering Corporation	Nucleic acids encoding a cytokine receptor complex
WO2002066516A2 (en)	2001-02-20	2002-08-29	Zymogenetics, Inc.	Antibodies that bind both bcma and taci
AT410637B (de) *	2001-06-01	2003-06-25	Igeneon Krebs Immuntherapie	Verwendung von polyklonalen immunglobulinen
WO2003037346A1 (en)	2001-10-31	2003-05-08	Cell Therapeutics, Inc.	6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
US7591994B2 (en)	2002-12-13	2009-09-22	Immunomedics, Inc.	Camptothecin-binding moiety conjugates
US8877901B2 (en)	2002-12-13	2014-11-04	Immunomedics, Inc.	Camptothecin-binding moiety conjugates
US9770517B2 (en)	2002-03-01	2017-09-26	Immunomedics, Inc.	Anti-Trop-2 antibody-drug conjugates and uses thereof
BR0314629A (pt)	2002-09-19	2005-08-02	Us Gov Health & Human Serv	Polipeptìdeos de p. ariasi polipeptìdeos de p. perniciosus e métodos e uso
US7419984B2 (en)	2002-10-17	2008-09-02	Cell Therapeutics, Inc.	Pyrimidines and uses thereof
JP2006516187A (ja)	2002-10-29	2006-06-29	アメリカ合衆国	ルツォーミアロンギパルピスポリペプチドおよび使用方法
US6875781B2 (en)	2003-04-04	2005-04-05	Cell Therapeutics, Inc.	Pyridines and uses thereof
US8562988B2 (en)	2005-10-19	2013-10-22	Ibc Pharmaceuticals, Inc.	Strategies for improved cancer vaccines
US8652484B2 (en)	2004-02-13	2014-02-18	Immunomedics, Inc.	Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8491914B2 (en) *	2004-02-13	2013-07-23	Ibc Pharmaceuticals, Inc.	Dock-and-lock (DNL) complexes for delivery of interference RNA
US8551480B2 (en)	2004-02-13	2013-10-08	Immunomedics, Inc.	Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US9481878B2 (en)	2004-02-13	2016-11-01	Immunomedics, Inc.	Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US20110020273A1 (en) *	2005-04-06	2011-01-27	Ibc Pharmaceuticals, Inc.	Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
US8435539B2 (en)	2004-02-13	2013-05-07	Immunomedics, Inc.	Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US20110064754A1 (en) *	2005-03-03	2011-03-17	Center For Molecular Medicine And Immunology	Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
PL2465534T3 (pl)	2004-06-10	2017-08-31	Omeros Corporation	Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
US7919094B2 (en)	2004-06-10	2011-04-05	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US8951522B2 (en)	2011-04-08	2015-02-10	University Of Leicester	Methods for treating conditions associated with MASP-2 dependent complement activation
GB0412966D0 (en)	2004-06-10	2004-07-14	Univ Leicester	Genetically modified non-human mammals and cells
WO2006042237A2 (en)	2004-10-06	2006-04-20	Mayo Foundation For Medical Education And Research	B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
WO2006086396A2 (en)	2005-02-08	2006-08-17	Zymogenetics, Inc.	Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
US9707302B2 (en)	2013-07-23	2017-07-18	Immunomedics, Inc.	Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CA2599734C (en)	2005-03-03	2014-01-28	Immunomedics, Inc.	Humanized l243 antibodies
US10058621B2 (en)	2015-06-25	2018-08-28	Immunomedics, Inc.	Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
ES2609429T3 (es)	2005-05-12	2017-04-20	Zymogenetics, Inc.	Composiciones y métodos para modular respuestas inmunitarias
EP1922338A2 (de) *	2005-06-03	2008-05-21	Widnes Company, Inc.	Polyklonales antiserum gegen ein universelles tumorantigen
WO2007019573A2 (en)	2005-08-09	2007-02-15	Zymogenetics, Inc.	Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
AU2006278229B2 (en)	2005-08-09	2011-10-27	Ares Trading S.A.	Methods for treating B-cell malignancies using TACI-Ig fusion molecule
EP2674440B1 (de)	2005-12-16	2019-07-03	IBC Pharmaceuticals, Inc.	Polyvalente bioaktive anordnungen auf immunglobulinbasis
EP1991274A4 (de)	2006-01-20	2009-06-10	Women S And Children S Health	Verfahren zur behandlung, prophylaxe und diagnose von knochenerkrankungen
JP2009529917A (ja)	2006-03-22	2009-08-27	ヴァイラルロジックシステムズテクノロジーコーポレーション	標的ポリペプチドの同定方法および免疫学的疾患の治療のためのその使用
KR20090016707A (ko)	2006-05-15	2009-02-17	아레스 트레이딩 에스.에이.	Ｔａｃｉｉｇ 융합 분자를 사용하여 자가면역 질병을 치료하는 방법
US8377448B2 (en)	2006-05-15	2013-02-19	The Board Of Trustees Of The Leland Standford Junior University	CD47 related compositions and methods for treating immunological diseases and disorders
US8008261B2 (en)	2006-08-04	2011-08-30	Mayo Foundation For Medical Education And Research	Methods of reducing trail-induced apoptosis by trail isoforms
JP5496897B2 (ja)	2007-10-04	2014-05-21	ザイモジェネティクス，インコーポレイテッド	Ｂ７ファミリーメンバーのｚＢ７Ｈ６ならびに関連する組成物および方法
EP2224954B1 (de) *	2007-11-07	2014-01-08	Celldex Therapeutics, Inc.	Menschliche dendritische und epithelzellen 205 (dec-205) bindende antikörper
KR101700711B1 (ko)	2007-11-21	2017-01-31	로스킬드 유니베르시테트	얼음-결합 활성을 포함하는 폴리펩티드
US8552155B2 (en)	2008-05-28	2013-10-08	Mayo Foundation For Medical Education And Research	Anti-Pyk2 antibodies
CA2734265C (en)	2008-08-20	2017-12-19	Ibc Pharmaceuticals, Inc.	Dock-and-lock (dnl) vaccines for cancer therapy
ES2738700T3 (es)	2009-02-13	2020-01-24	Immunomedics Inc	Inmunoconjugados con un enlace escindible intracelularmente
WO2011003100A2 (en)	2009-07-02	2011-01-06	Massachusetts Institute Of Technology	Compositions and methods for diagnosing and/or treating influenza infection
US20120269765A1 (en)	2009-07-24	2012-10-25	Garcia K Christopher	Cytokine compositions and methods of use thereof
AU2010306581B2 (en)	2009-10-16	2015-03-19	Omeros Corporation	Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
US20120322085A1 (en)	2009-11-05	2012-12-20	Osaka University	Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
WO2011159826A2 (en)	2010-06-15	2011-12-22	Vertex Pharmaceuticals Incorporated	Hcv ns5b protease mutants
EP2640405A4 (de)	2010-09-21	2015-04-15	Massachusetts Inst Technology	An den menschen angepasste ha-polypeptide, impfstoffe daraus und influenza-behandlung damit
SG10201709806VA (en)	2010-10-04	2017-12-28	Massachusetts Inst Technology	Hemagglutinin polypeptides, and reagents and methods relating thereto
US20140308242A1 (en)	2010-10-21	2014-10-16	Vertex Pharmaceuticals Incorporated	Biomarkers for hcv infected patients
WO2012057765A1 (en)	2010-10-28	2012-05-03	The Board Of Regents Of The University Of Texas System	Recombinant anti-cd19 monoclonal antibodies
US9644035B2 (en)	2011-04-08	2017-05-09	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
AU2012271336B2 (en)	2011-06-17	2017-03-02	University Of Tennessee Research Foundation	Group A streptococcus multivalent vaccine
US9757458B2 (en)	2011-12-05	2017-09-12	Immunomedics, Inc.	Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
WO2013085893A1 (en)	2011-12-05	2013-06-13	Immunomedics, Inc.	Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US9421250B2 (en)	2012-03-23	2016-08-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pathogenic phlebovirus isolates and compositions and methods of use
EP2833907B1 (de)	2012-04-06	2018-02-28	Omeros Corporation	Zusammensetzungen und verfahren zur hemmung von masp-1 und/oder masp-3 zur behandlung von paroxysmaler nächtlicher hämoglobinurie
WO2013169377A1 (en)	2012-05-10	2013-11-14	Massachusetts Institute Of Technology	Agents for influenza neutralization
KR20200015952A (ko)	2012-06-18	2020-02-13	오메로스 코포레이션	다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
WO2014015217A1 (en)	2012-07-19	2014-01-23	Vertex Pharmaceuticals Incorporated	Biomarkers for hcv infected patients
EP2885002A4 (de)	2012-08-14	2016-04-20	Ibc Pharmaceuticals Inc	Umleitung t-zell-bispezifischer antikörper zur behandlung von krankheiten
US12310958B2 (en)	2012-12-13	2025-05-27	Immunomedics, Inc.	Antibody-drug conjugates and uses thereof
ES2819573T3 (es)	2012-12-13	2021-04-16	Immunomedics Inc	Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
US9931417B2 (en)	2012-12-13	2018-04-03	Immunomedics, Inc.	Antibody-SN-38 immunoconjugates with a CL2A linker
US10413539B2 (en)	2012-12-13	2019-09-17	Immunomedics, Inc.	Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10137196B2 (en)	2012-12-13	2018-11-27	Immunomedics, Inc.	Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US20240139324A1 (en)	2012-12-13	2024-05-02	Immunomedics, Inc.	Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
AU2013360335B2 (en)	2012-12-13	2017-12-07	Immunomedics, Inc.	Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10744129B2 (en)	2012-12-13	2020-08-18	Immunomedics, Inc.	Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US10206918B2 (en)	2012-12-13	2019-02-19	Immunomedics, Inc.	Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US9492566B2 (en)	2012-12-13	2016-11-15	Immunomedics, Inc.	Antibody-drug conjugates and uses thereof
US9448232B2 (en)	2013-01-24	2016-09-20	Mayo Foundation For Medical Education And Research	Methods and materials for detecting C9ORF72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or C9ORF72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
EP2953967B1 (de)	2013-02-07	2019-05-01	Massachusetts Institute of Technology	Menschliche anpassung von h5-influenza
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
JP2016515216A (ja)	2013-03-14	2016-05-26	シャイアーヒューマンジェネティックセラピーズインコーポレイテッド	メッセンジャーｒｎａのキャップ効率の定量的評価
EA201591993A1 (ru)	2013-05-23	2016-05-31	Шир Хьюман Дженетик Терапис, Инк.	Лечение склеродермии с применением комбинированной терапии антителами анти-ccl2 и анти-loxl2
WO2014197723A2 (en)	2013-06-05	2014-12-11	Massachusetts Institute Of Technology	Human adaptation of h7 ha
WO2014202089A2 (en)	2013-06-18	2014-12-24	Roskilde Universitet	Variants of anti-freeze polypeptides
US11253606B2 (en)	2013-07-23	2022-02-22	Immunomedics, Inc.	Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3052131B1 (de)	2013-10-01	2018-12-05	Mayo Foundation for Medical Education and Research	Verfahren zur krebsbehandlung bei patienten mit erhöhtem bim-spiegel
LT3057993T (lt)	2013-10-17	2020-11-25	Omeros Corporation	Gydymo būdai būklių, susijusių su nuo masp-2 priklausomu komplemento aktyvinimu
US20150174242A1 (en)	2013-12-19	2015-06-25	Mayo Foundation For Medical Education And Research	Monovalent anti-cd3 adjuvants
CN106029098A (zh)	2014-02-25	2016-10-12	免疫医疗公司	人源化rfb4抗cd22抗体
KR102380402B1 (ko)	2014-04-03	2022-03-31	아이쥐엠 바이오사이언스 인코포레이티드	변형된 j-사슬
US9833512B2 (en)	2014-04-09	2017-12-05	Mayo Foundation For Medical Education And Research	Blocking IL-9 signaling in conjunction with chemotherapy to treat cancer
US10302653B2 (en)	2014-05-22	2019-05-28	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti B7-H1 antibodies
WO2016007742A1 (en)	2014-07-09	2016-01-14	Riester Scott M	Treating rotator cuff conditions
WO2016014148A1 (en)	2014-07-23	2016-01-28	Mayo Foundation For Medical Education And Research	Targeting dna-pkcs and b7-h1 to treat cancer
CA2961774C (en)	2014-10-07	2023-05-23	Immunomedics, Inc.	Neoadjuvant use of antibody-drug conjugates
WO2016146134A1 (en)	2015-03-16	2016-09-22	Aarhus Universitet	Antibodies towards an extracellular region of nbcn1
US9797907B2 (en)	2015-04-22	2017-10-24	Immunomedics, Inc.	Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
US10195175B2 (en)	2015-06-25	2019-02-05	Immunomedics, Inc.	Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
JP6980980B2 (ja)	2015-06-25	2021-12-15	イミューノメディクス、インコーポレイテッドImmunomedics, Inc.	抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
EP3316885B1 (de)	2015-07-01	2021-06-23	Immunomedics, Inc.	Antikörper-sn-38-immunkonjugate mit einem cl2a-linker
EP3322481A4 (de)	2015-07-16	2019-03-06	Mayo Foundation for Medical Education and Research	Behandlung von rotatormanschettenleiden
WO2017075045A2 (en)	2015-10-30	2017-05-04	Mayo Foundation For Medical Education And Research	Antibodies to b7-h1
US20170137537A1 (en)	2015-11-09	2017-05-18	Omeros Corporation	Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
WO2017117130A1 (en)	2015-12-28	2017-07-06	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
CA3010593C (en)	2016-01-05	2024-02-13	University Of Leicester	Methods for inhibiting fibrosis in a subject in need thereof
CN108601841A (zh)	2016-02-10	2018-09-28	免疫医疗公司	Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
CN109152834A (zh)	2016-03-31	2019-01-04	奥默罗斯公司	抑制有需要的受试者的血管发生的方法
WO2017189279A1 (en)	2016-04-27	2017-11-02	Immunomedics, Inc.	Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
EP3450460B1 (de)	2016-04-29	2023-07-12	Benhealth Biopharmaceutic (Shenzhen) Co. Ltd.	Multispezifisches bindungskonjugat, entsprechende pharmazeutische zusammensetzungen und verwendung
WO2018055031A1 (en)	2016-09-21	2018-03-29	Aarhus Universitet	Acid-base transport inhibitors
EP3600283A4 (de)	2017-03-27	2020-12-16	Immunomedics, Inc.	Behandlung von trop-2-exprimierendem triple-negativem brustkrebs mit sacituzumab govitecan und einem rad51-hemmer
US10799597B2 (en)	2017-04-03	2020-10-13	Immunomedics, Inc.	Subcutaneous administration of antibody-drug conjugates for cancer therapy
TWI818919B (zh)	2017-08-15	2023-10-21	美商歐米諾斯公司	用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
JP7241069B2 (ja)	2017-09-25	2023-03-16	フレッドハッチンソンキャンサーセンター	高効率標的ｉｎｓｉｔｕゲノムワイドプロファイリング
WO2019090284A1 (en)	2017-11-06	2019-05-09	Mayo Foundation For Medical Education And Research	Methods and materials for identifying and treating cancers having elevated levels of phosphorylated ubiquitin
KR20210016545A (ko)	2018-05-29	2021-02-16	오메로스 코포레이션	Masp-2 억제제 및 사용 방법
US11584714B2 (en)	2018-05-29	2023-02-21	Omeros Corporation	MASP-2 inhibitors and methods of use
US12257286B2 (en)	2018-10-31	2025-03-25	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
WO2020092839A1 (en)	2018-10-31	2020-05-07	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
WO2021113682A1 (en)	2019-12-04	2021-06-10	Omeros Corporation	Masp-2 inhibitors and methods of use
WO2021113686A1 (en)	2019-12-04	2021-06-10	Omeros Corporation	Masp-2 inhibitors and methods of use
EP4069676A1 (de)	2019-12-04	2022-10-12	Omeros Corporation	Masp-2-hemmer und verfahren zur verwendung
BR112022017064A2 (pt)	2020-02-25	2022-11-16	Mediboston Inc	Derivados da camptotecina e seus conjugados
TWI867422B (zh)	2020-03-06	2024-12-21	美商奥默羅斯公司	用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
US11795228B2 (en)	2020-09-30	2023-10-24	Dren Bio, Inc.	Anti-CD94 antibodies and methods of use thereof
US12521444B2 (en)	2021-02-25	2026-01-13	Fortvita Biologics Limited	Anti-HER2 antibody-drug conjugates and uses thereof
TW202412762A (zh)	2022-07-27	2024-04-01	香港商祐方有限公司	奧瑞他汀衍生物及其結合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4624846A (en) *	1983-07-29	1986-11-25	Immunomedics, Inc.	Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
EP0291636A1 (de) *	1983-11-07	1988-11-23	The Wistar Institute	Von Anti-Idiotyp-Antikörpern induzierte Immunreaktion gegen Viren
US5053224A (en)	1983-11-07	1991-10-01	Hilary Koprowski	Induction of antibody response to solid tumors with anti-idiotype antibodies
US4777245A (en) *	1984-01-06	1988-10-11	Genelabs Incorporated	Non-human primate monoclonal antibodies and methods
US4918164A (en) *	1987-09-10	1990-04-17	Oncogen	Tumor immunotherapy using anti-idiotypic antibodies
US5101017A (en) *	1987-04-06	1992-03-31	New York Blood Center, Inc.	Antibodies for providing protection against P. vivax malaria infection
US4908203A (en) *	1987-09-09	1990-03-13	Johnson & Johnson	Method for inducing HIV neutralizing antibodies using an internal image idiotope
PT89107A (pt) *	1987-11-30	1989-11-30	Idec Pharma Corp	Metodo e meios para a seleccao de anticorpos anti-idiotipos e seu uso para o diagnostico, monitorizacao, tratamento e/ou prevencao de doencas cancerosas, da autoimunidade ou infecciosas
US5721349A (en) *	1992-02-26	1998-02-24	Vanderbilt University	Vacuolating toxin-deficient H. pylori
EP0719155A1 (de) *	1993-08-27	1996-07-03	Enteric Research Laboratories, Inc.	ANTIGENE VON $i(CAMPYLOBACTER JEJUNI), UND VERFAHREN FÜR IHRE HERSTELLUNG UND VERWENDUNG
US6730300B2 (en) *	1996-03-20	2004-05-04	Immunomedics, Inc.	Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications

1990
- 1990-12-28 SG SG1996004733A patent/SG46445A1/en unknown
- 1990-12-28 EP EP90125701A patent/EP0438803B1/de not_active Expired - Lifetime
- 1990-12-28 DE DE69030172T patent/DE69030172T2/de not_active Expired - Fee Related
- 1990-12-28 AT AT90125701T patent/ATE149841T1/de not_active IP Right Cessation
- 1990-12-31 AU AU71581/91A patent/AU641470B2/en not_active Ceased
- 1990-12-31 WO PCT/US1990/007527 patent/WO1991011465A1/en not_active Ceased
- 1990-12-31 JP JP3502872A patent/JP2919071B2/ja not_active Expired - Fee Related
1991
- 1991-01-04 CA CA002033640A patent/CA2033640C/en not_active Expired - Lifetime
- 1991-01-07 IL IL9689391A patent/IL96893A/en not_active IP Right Cessation
- 1991-01-25 IE IE026591A patent/IE910265A1/en not_active IP Right Cessation
- 1991-01-25 ZA ZA91559A patent/ZA91559B/xx unknown
1992
- 1992-01-02 US US08/183,381 patent/US6440416B1/en not_active Expired - Lifetime
2002
- 2002-08-19 US US10/222,914 patent/US20020192227A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2033640C (en)	2005-10-18
US6440416B1 (en)	2002-08-27
IE910265A1 (en)	1991-07-31
AU641470B2 (en)	1993-09-23
DE69030172T2 (de)	1997-06-19
AU7158191A (en)	1991-08-21
CA2033640A1 (en)	1991-07-27
EP0438803A2 (de)	1991-07-31
WO1991011465A1 (en)	1991-08-08
EP0438803B1 (de)	1997-03-12
ATE149841T1 (de)	1997-03-15
IL96893A0 (en)	1992-03-29
US20020192227A1 (en)	2002-12-19
ZA91559B (en)	1991-11-27
JP2919071B2 (ja)	1999-07-12
DE69030172D1 (de)	1997-04-17
EP0438803A3 (en)	1991-10-16
JPH10510509A (ja)	1998-10-13
SG46445A1 (en)	1998-02-20

Legal Events

Date	Code	Title
1997-04-15	KB	Patent renewed
2001-06-14	KB	Patent renewed
2005-02-20	KB	Patent renewed
2009-07-27	KB	Patent renewed
2011-09-27	EXP	Patent expired

Publication	Publication Date	Title
US6440416B1 (en)	2002-08-27	Vaccines against cancer and infectious diseases
US6812024B2 (en)	2004-11-02	Anti-paratopic antibody as an immunogen
US20080131443A1 (en)	2008-06-05	Method and composition for reconforming multi-epitopic antigens to intiate an immune response
JP2633807B2 (ja)	1997-07-23	抗イデイオタイプ抗体を産生するイモータルリンパ球
Snider et al.	1990	Enhanced antigen immunogenicity induced by bispecific antibodies.
US6124132A (en)	2000-09-26	Use of anti-HIV IGA antibodies for producing immunological protection against the human immunodeficiency virus
Cosenza et al.	1977	Idiotypes and anti-idiotypes as probes in analysis of immunoregulation
EP0440689B1 (de)	1995-11-29	Anti-idiotyp antikörper induktion eines antitumorenresponses
Losman et al.	1991	Human response against NP-4, a mouse antibody to carcinoembryonic antigen: human anti-idiotype antibodies mimic an epitope on the tumor antigen.
FI111518B (fi)	2003-08-15	Menetelmä monoklonaalisten vasta-aineiden ja vasta-ainetta sisältävän farmaseuttisen koostumuksen valmistamiseksi
US20090202560A1 (en)	2009-08-13	Method for diagnosing efficacy of xenotypic antibody therapy
CA1341277C (en)	2001-07-31	Anti-paratopic antibody and a method of its manufacture
Landon et al.	2012	Therapeutic antibodies
CA1341566C (en)	2007-12-18	Immune response to tumors induced by anti-idiotype antibodies
Shoenfeld et al.	1997	Anti-idiotypic antibodies that mimic the colorectal cancer antigen CO17-1A/GA733: twelve years of pre-clinical and clinical studies
RU2014845C1 (ru)	1994-06-30	Способ получения вакцины против спида
AU711270C (en)	2000-12-21	Method and composition for reconforming multi-epitopic antigens to initiate an immune response
AU628286B2 (en)	1992-09-17	Anti-paratopic antibody as an immunogen
Arulanandam	1990	Antigen mimicking monoclonal anti-idiotypic antibodies to distinct determinants on S. agalactiae.
Poskitt et al.	1991	The Immune Response to Anti-Idiotype Antibodies Bearing an Internal Image Epitope of Tetanus Toxin/Toxoid: I. Induction of the Humoral Immune Response
MXPA98009586A (en)	2000-06-05	Method and composition for the reconformation of multi-peptide antigens to start an animal response